Amarin Corporation PLC To Present At C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference

LONDON, October 24 /PRNewswire-FirstCall/ -- Amarin Corporation plc announced today that Rick Stewart, Chief Executive Officer, will present a company update at C.E. Unterberg, Towbin's Emerging Growth Life Sciences Conference. A presentation will be made on Wednesday , October 26th, 2005 at 8.40 a.m. The conference is being held at The Palace Hotel, New York City on October 25th and 26th.

This presentation will be simultaneously webcast and a link will be provided on Amarin Corporation's website www.amarincorp.com

Contact: Amarin Corporation plc +44-(0)-207-907-2442 Rick Stewart Chief Executive Officer Alan Cooke Chief Financial Officer investor.relations@amarincorp.com Powerscourt +44-(0)-207-236-5615 Rory Godson/Victoria Brough About Amarin Corporation

Amarin Corporation plc is a neuroscience company focused on the development and commercialization of novel drugs for the treatment of central nervous system disorders. Miraxion, Amarin's lead development compound, is in phase III development for Huntington's disease and in phase II development for depression.

For press releases and other corporate information, visit our website at http://www.amarincorp.com.

DISCLOSURE NOTICE: The information contained in this document is as of 24th October, 2005. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments.

This document contains forward-looking statements about Amarin's financial condition, results of operations, business prospects and products in research that involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: the success of Amarin's research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affective Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating requirements; general changes in U.K. and U.S. generally accepted accounting principles; growth in costs and expenses; and the impact of acquisitions, divestitures and other unusual items, including Amarin's ability to integrate its acquisition of Amarin Neuroscience Limited. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Annual Report on Form 20-F for the fiscal year ended December 31, 2004, and in its Reports of Foreign Issuer on Form 6-K filed with the SEC.

CONTACT: Contact: Amarin Corporation plc: +44-(0)207-907-2442 (RickStewart, Chief Executive Officer, Alan Cooke, Chief Financial Officer),investor.relations@amarincorp.com. Powerscourt: +44-(0)207-236-5615 (RoryGodson/Victoria Brough)